This combination pairs Tesamorelin, a stabilized 44-amino-acid analogue of growth hormone-releasing hormone (GHRH), with Ipamorelin, a highly selective pentapeptide growth hormone secretagogue. Each compound acts on a distinct receptor within the somatotropic axis, and researchers study the pair together to examine how GHRH-receptor and ghrelin-receptor signaling interact in models of pulsatile growth hormone release.
This combination pairs Tesamorelin, a stabilized 44-amino-acid analogue of growth hormone-releasing hormone (GHRH), with Ipamorelin, a highly selective pentapeptide growth hormone secretagogue. Each compound acts on a distinct receptor within the somatotropic axis, and researchers study the pair together to examine how GHRH-receptor and ghrelin-receptor signaling interact in models of pulsatile growth hormone release.
Tesamorelin / Ipamorelin (Tesamorelin + Ipamorelin Combination) is supplied strictly as a reference material for in vitro and preclinical investigation. All characterization data described here is drawn from peer-reviewed literature and laboratory analysis; nothing herein constitutes a claim of clinical effect in humans.
The following domains summarize directions explored across published studies and laboratory models. Each reflects observations reported in rodent models, in vitro systems, or the peer-reviewed record.
Tesamorelin acts at the GHRH receptor while Ipamorelin acts at the growth hormone secretagogue receptor. Research has examined whether concurrent stimulation of both receptors produces greater amplitude of pulsatile GH release than either pathway alone in animal models.
Tesamorelin is among the most studied GHRH analogues for visceral fat reduction, with documented reductions in trunk fat accumulation in models of GH-axis insufficiency. The combination is used by researchers examining lipolytic endpoints alongside GH pulse characteristics.
Ipamorelin is documented as one of the most selective GHRPs, showing minimal effect on cortisol, prolactin, and ACTH in published animal studies. Researchers use it alongside GHRH analogues to study GH release with limited confounding from other pituitary hormones.
Published work on GHRH-analogue plus GHRP co-administration has examined additive and synergistic secretory responses. Standardized two-compound preparations allow researchers to hold the ratio of the two peptides constant across experimental groups.
Mechanistic steps below are hypothesized from in vitro assays and animal-model data reported in the literature. They describe biochemical interactions observed under controlled experimental conditions.
Tesamorelin is a full agonist at the GHRH receptor (GHRHR) on pituitary somatotroph cells, stimulating GH synthesis and pulsatile secretion through the same cAMP-dependent pathway as endogenous GHRH.
Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor, triggering a calcium-dependent secretory response in somatotrophs that is mechanistically separate from GHRH receptor signaling.
Because the two compounds recruit different second-messenger cascades that converge on the same somatotroph population, research has examined whether the combined secretory response exceeds the sum of the individual responses.
The trans-3-hexenoic acid modification on Tesamorelin protects it from rapid degradation by dipeptidyl peptidase IV (DPP-IV), extending its biological half-life relative to native GHRH and lengthening the window over which both compounds are active.
| Amino Acid Sequence | Tesamorelin: Trans-3-hexenoic acid-GRF(1-44)-NH₂ | Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ |
|---|---|
| Molecular Weight | Tesamorelin: 5,135.8 g/mol | Ipamorelin: 711.9 g/mol |
| Molecular Formula | Tesamorelin: C₂₂₁H₃₆₆N₇₂O₆₇S | Ipamorelin: C₃₈H₄₉N₉O₅ |
| CAS Number | Tesamorelin: 218949-48-5 | Ipamorelin: 170851-70-4 |
| Storage | −20°C long-term, 4°C short-term up to 4 weeks |
The following peer-reviewed references informed the research summaries on this page. Citations are provided for scientific context only.
This product is intended strictly for laboratory research purposes only. It is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or animal consumption. All information presented is derived from published scientific literature and is provided for educational reference only. By purchasing, the buyer affirms they are a qualified researcher or institution and assume full responsibility for the safe and lawful handling of this material.